ATE345816T1 - Antithrombose agenzien - Google Patents
Antithrombose agenzienInfo
- Publication number
- ATE345816T1 ATE345816T1 AT00968710T AT00968710T ATE345816T1 AT E345816 T1 ATE345816 T1 AT E345816T1 AT 00968710 T AT00968710 T AT 00968710T AT 00968710 T AT00968710 T AT 00968710T AT E345816 T1 ATE345816 T1 AT E345816T1
- Authority
- AT
- Austria
- Prior art keywords
- agents
- antithrobic
- fixabs
- suk
- streptokinase
- Prior art date
Links
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 2
- 229960005356 urokinase Drugs 0.000 abstract 2
- 108010001014 Plasminogen Activators Proteins 0.000 abstract 1
- 102000001938 Plasminogen Activators Human genes 0.000 abstract 1
- 108010023197 Streptokinase Proteins 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940127126 plasminogen activator Drugs 0.000 abstract 1
- 229960005202 streptokinase Drugs 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57143400A | 2000-05-15 | 2000-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345816T1 true ATE345816T1 (de) | 2006-12-15 |
Family
ID=24283688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00968710T ATE345816T1 (de) | 2000-05-15 | 2000-10-05 | Antithrombose agenzien |
Country Status (20)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222020B2 (en) | 2002-03-20 | 2008-08-28 | University Of Maryland Baltimore | A non-selective cation channel in neural cells and methods for treating brain swelling |
| US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| JP5307397B2 (ja) * | 2004-09-18 | 2013-10-02 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法 |
| JP5085326B2 (ja) | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
| CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
| WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
| DK3002298T3 (da) * | 2007-11-21 | 2019-10-28 | Univ Oregon Health & Science | Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf |
| GB201121513D0 (en) * | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
| US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
| KR102702288B1 (ko) * | 2016-12-23 | 2024-09-05 | 노파르티스 아게 | 항-인자 XI/XIa 항체를 사용한 치료 방법 |
| US20240018503A1 (en) * | 2017-04-27 | 2024-01-18 | Chugai Seiyaku Kabushiki Kaisha | Coagulation factor ix with improved pharmacokinetics |
| WO2018199214A1 (ja) | 2017-04-27 | 2018-11-01 | 中外製薬株式会社 | 薬物動態が改善された血液凝固第ｉｘ因子 |
| CN115448985A (zh) * | 2021-06-08 | 2022-12-09 | 上海循曜生物科技有限公司 | 新型抗栓抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2049655C (en) * | 1990-09-17 | 1996-11-12 | Akio Odawara | Pharmaceutical composition for inhibiting platelet aggregation |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| WO2000007626A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| AU766551C (en) * | 1998-08-28 | 2005-02-17 | Genentech Inc. | Human anti-factor IX/IXa antibodies |
-
2000
- 2000-10-05 JP JP2001583806A patent/JP2004516236A/ja active Pending
- 2000-10-05 CN CNB008197237A patent/CN100339132C/zh not_active Expired - Fee Related
- 2000-10-05 MX MXPA02011385A patent/MXPA02011385A/es active IP Right Grant
- 2000-10-05 EP EP06124420A patent/EP1825864A3/en active Pending
- 2000-10-05 EP EP00968710A patent/EP1282444B1/en not_active Expired - Lifetime
- 2000-10-05 NZ NZ522632A patent/NZ522632A/en unknown
- 2000-10-05 BR BR0015872-0A patent/BR0015872A/pt not_active IP Right Cessation
- 2000-10-05 AT AT00968710T patent/ATE345816T1/de not_active IP Right Cessation
- 2000-10-05 KR KR1020027015403A patent/KR20030034071A/ko not_active Ceased
- 2000-10-05 HU HU0301804A patent/HU225874B1/hu not_active IP Right Cessation
- 2000-10-05 CN CNA200710141110XA patent/CN101134107A/zh active Pending
- 2000-10-05 ES ES00968710T patent/ES2277597T3/es not_active Expired - Lifetime
- 2000-10-05 IL IL15283100A patent/IL152831A0/xx unknown
- 2000-10-05 DE DE60032029T patent/DE60032029T2/de not_active Expired - Fee Related
- 2000-10-05 CA CA002411369A patent/CA2411369A1/en not_active Abandoned
- 2000-10-05 WO PCT/US2000/027438 patent/WO2001087339A1/en not_active Ceased
- 2000-10-05 AU AU7858400A patent/AU7858400A/xx active Pending
- 2000-10-05 PL PL36006000A patent/PL360060A1/xx unknown
- 2000-10-05 AU AU2000278584A patent/AU2000278584B2/en not_active Ceased
- 2000-10-05 KR KR1020077027348A patent/KR20070116192A/ko not_active Ceased
- 2000-10-05 CZ CZ20023778A patent/CZ20023778A3/cs unknown
-
2002
- 2002-11-14 NO NO20025463A patent/NO20025463L/no not_active Application Discontinuation
- 2002-11-14 ZA ZA200209265A patent/ZA200209265B/xx unknown
-
2003
- 2003-08-11 US US10/638,777 patent/US20050037006A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070116192A (ko) | 2007-12-06 |
| CN1501812A (zh) | 2004-06-02 |
| ES2277597T3 (es) | 2007-07-16 |
| HUP0301804A2 (hu) | 2003-08-28 |
| BR0015872A (pt) | 2004-08-03 |
| CN100339132C (zh) | 2007-09-26 |
| ZA200209265B (en) | 2003-10-22 |
| DE60032029T2 (de) | 2007-05-31 |
| CZ20023778A3 (cs) | 2003-08-13 |
| HUP0301804A3 (en) | 2005-12-28 |
| DE60032029D1 (de) | 2007-01-04 |
| MXPA02011385A (es) | 2004-01-26 |
| PL360060A1 (en) | 2004-09-06 |
| EP1282444B1 (en) | 2006-11-22 |
| EP1282444A4 (en) | 2004-06-30 |
| NZ522632A (en) | 2005-05-27 |
| EP1825864A3 (en) | 2007-09-12 |
| JP2004516236A (ja) | 2004-06-03 |
| CA2411369A1 (en) | 2001-11-22 |
| EP1825864A2 (en) | 2007-08-29 |
| WO2001087339A1 (en) | 2001-11-22 |
| HU225874B1 (en) | 2007-11-28 |
| AU2000278584B2 (en) | 2006-11-16 |
| IL152831A0 (en) | 2003-06-24 |
| KR20030034071A (ko) | 2003-05-01 |
| US20050037006A1 (en) | 2005-02-17 |
| NO20025463L (no) | 2003-01-09 |
| CN101134107A (zh) | 2008-03-05 |
| NO20025463D0 (no) | 2002-11-14 |
| EP1282444A1 (en) | 2003-02-12 |
| AU7858400A (en) | 2001-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE345816T1 (de) | Antithrombose agenzien | |
| DE60042214D1 (cg-RX-API-DMAC7.html) | ||
| ATE307111T1 (de) | Serinprotease-inhibitoren | |
| ATE260246T1 (de) | Selektive inhibitoren des urokinase-plasminogen aktivators | |
| WO2003057831A3 (en) | Dtat fusion toxin | |
| DK0669394T3 (da) | Bifunktionelle urokinasevarianter med forbedrede fibrinolytiske egenskaber og thrombinhæmmende virkninger | |
| EP0692968A4 (en) | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | |
| WO2003053999A3 (de) | Selektive arylguanidinpeptide als urokinaseinhibitoren | |
| ATE103332T1 (de) | Modifizierter gewebeplasminogenaktivator. | |
| DE59001558D1 (de) | Thrombolytisch wirkendes kombinationspraeparat. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |